An engineered cell membrane to PD-1 receptor-presenting membrane-encapsulated paclitaxel dimer NPs (PD-1@PTX 2 NPs) selectively binds to PD-L1 ligands on the BC surface and can release NPs, resulting in a 3.2-fold depletion of Tregs in vivo in mice, exhibiting a 71.3% tumor growth inhibition [270], using anti-CD80 antibody-modified biodegradable PCL-Hyd-PEG vesicles carrying NP (EAC-NP), combined with the HSP70 chaperoning polypeptide (HCP) and a demethylated CpG matrix (CpG ODN) adjuvant. This evidence concerns the gene CD80 and breast cancer.